The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Antifungal susceptibility testing of isolates from a randomized, multicenter trial of fluconazole versus amphotericin B as treatment of nonneutropenic patients with candidemia. NIAID Mycoses Study Group and the Candidemia Study Group
Open accessAbstract
The antifungal susceptibilities of 232 pathogenic blood stream Candida isolates collected during a recently completed trial comparing fluconazole (400 mg/day) with amphotericin B (0.5 mg/kg of body weight per day) as treatment for candidemia in the nonneutropenic patient were determined both by the National committee for Clinical Laboratory Standards M27-P macrobroth methodology and by a less cumbersome broth microdilution methodology. For amphotericin B, M27-P yielded a very narrow range of MICs (0.125 to 1 microgram/ml) and there were no susceptibility differences among species. For fluconazole, a broad range of MICs were seen (0.125 to > 64 micrograms/ml), with characteristic MICs seen for each species in the rank order Candida albicans < C. parapsilosis approximately equal to C. lusitaniae < C. glabrata approximately equal to C. krusei approximately equal to C. lipolytica. The MIC distribution for C. tropicalis was bimodal and could not be ranked. Both microdilution MICs were within one tube dilution of the M27-P MIC for > 90% of isolates with amphotericin B and for > or = 77% of isolates with fluconazole. For both methods, elevated MICs did not predict treatment failure. In the case of amphotericin B, the MIC range was too narrow to permit identification of resistant isolates. In the case of fluconazole, MICs for isolates associated with failure to clear the bloodstream consistently were equivalent to the median MIC for the given species. Successful courses of therapy were seen with four isolates from four patients despite MICs of > or = 32 micrograms/ml. As MICs obtained by M27-P and similar methods correlate with responsiveness to fluconazole therapy in animal models and in AIDS patients with oropharyngeal candidiasis, the lack of correlation in this setting suggests that the MICs for these isolates are at or below the relevant fluconazole breakpoint for this dose of fluconazole and patient setting and that host factors such as failure to exchange intravenous catheters were more important than MIC in predicting outcome.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
National Committee for Clinical Laboratory Standards
Bruck, E. (1980) · Pediatrics · doi:10.1542/peds.65.1.187 · Cited by 14,751
Manual of Clinical Microbiology.
(1980) · Annals of Internal Medicine · doi:10.7326/0003-4819-93-6-939_2 · Cited by 14,411
Antibiotics in Laboratory Medicine.
(1980) · Annals of Internal Medicine · doi:10.7326/0003-4819-93-4-653_4 · Cited by 2,779
Manual of Clinical Microbiology.
(1970) · Annals of Internal Medicine · doi:10.7326/0003-4819-73-3-501_3 · Cited by 1,315
Antifungal susceptibility testing
Rex, J. H., Pfaller, M. A., Rinaldi, M. G., Polak, A., & Galgiani, J. N. (1993) · Clinical Microbiology Reviews · doi:10.1128/cmr.6.4.367 · Cited by 361
Self-citationRedding, S., Smith, J., Farinacci, G., Rinaldi, M., Fothergill, A., Rhine-Chalberg, J., & Pfaller, M. (1994) · Clinical Infectious Diseases · doi:10.1093/clinids/18.2.240 · Cited by 269
Self-citationCollaborative comparison of broth macrodilution and microdilution antifungal susceptibility tests
Espinel-Ingroff, A., Kish, C. W., Kerkering, T. M., Fromtling, R. A., Bartizal, K., Galgiani, J. N., Villareal, K., Pfaller, M. A., Gerarden, T., & Rinaldi, M. G. (1992) · Journal of Clinical Microbiology · doi:10.1128/jcm.30.12.3138-3145.1992 · Cited by 243
Self-citationMillon, L., Manteaux, A., Reboux, G., Drobacheff, C., Monod, M., Barale, T., & Michel-Briand, Y. (1994) · Journal of Clinical Microbiology · doi:10.1128/jcm.32.4.1115-1118.1994 · Cited by 205
Multicenter evaluation of a broth macrodilution antifungal susceptibility test for yeasts
Fromtling, R. A., Galgiani, J. N., Pfaller, M. A., Espinel-Ingroff, A., Bartizal, K. F., Bartlett, M. S., Body, B. A., Frey, C., Hall, G., & Roberts, G. D. (1993) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.37.1.39 · Cited by 196
Self-citationPfaller, M. A., & Barry, A. L. (1994) · Journal of Clinical Microbiology · doi:10.1128/jcm.32.8.1992-1996.1994 · Cited by 160
Self-citation
Cited by
Guidelines for Treatment of Candidiasis
Pappas, P. G., Rex, J. H., Sobel, J. D., Filler, S. G., Dismukes, W. E., Walsh, T. J., & Edwards, J. E. (2004) · Clinical Infectious Diseases · doi:10.1086/380796 · Cited by 1,440
Self-citationCurrent and emerging azole antifungal agents
Sheehan, D. J., Hitchcock, C. A., & Sibley, C. M. (1999) · Clinical Microbiology Reviews · doi:10.1128/cmr.12.1.40 · Cited by 1,137
Fidel, P. L., Vazquez, J. A., & Sobel, J. D. (1999) · Clinical Microbiology Reviews · doi:10.1128/cmr.12.1.80 · Cited by 953
Practice Guidelines for the Treatment of Candidiasis
Rex, J. H., Walsh, T. J., Sobel, J. D., Filler, S. G., Pappas, P. G., Dismukes, W. E., & Edwards, J. E. (2000) · Clinical Infectious Diseases · doi:10.1086/313749 · Cited by 927
Self-citationEpidemiology of Candida species infections in critically ill non-immunosuppressed patients
Eggimann, P., Garbino, J., & Pittet, D. (2003) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(03)00801-6 · Cited by 900
Resistance of Candida species to fluconazole
Rex, J. H., Rinaldi, M. G., & Pfaller, M. A. (1995) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.39.1.1 · Cited by 877
Self-citationResistance of Candida species to antifungal agents: molecular mechanisms and clinical consequences
Sanglard, D., & Odds, F. C. (2002) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(02)00181-0 · Cited by 784
Non-albicans Candida spp. causing fungaemia: pathogenicity and antifungal resistance
Krcmery, V., & Barnes, A. J. (2002) · Journal of Hospital Infection · doi:10.1053/jhin.2001.1151 · Cited by 733
New and emerging yeast pathogens
Hazen, K. C. (1995) · Clinical Microbiology Reviews · doi:10.1128/cmr.8.4.462 · Cited by 614
Antifungal drug resistance of pathogenic fungi
Kontoyiannis, D. P., & Lewis, R. E. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08162-x · Cited by 553
Nosocomial Candidiasis: Emerging Species, Reservoirs, and Modes of Transmission
Pfaller, M. A. (1996) · Clinical Infectious Diseases · doi:10.1093/clinids/22.supplement_2.s89 · Cited by 502
Self-citationYarrowia lipolytica: Safety assessment of an oleaginous yeast with a great industrial potential
Groenewald, M., Boekhout, T., Neuvéglise, C., Gaillardin, C., van Dijck, P. W. M., & Wyss, M. (2014) · Critical Reviews in Microbiology · doi:10.3109/1040841x.2013.770386 · Cited by 498
Pfaller, M. A., & Diekema, D. J. (2012) · Journal of Clinical Microbiology · doi:10.1128/jcm.00937-12 · Cited by 484
Self-citationKao, A. S., Brandt, M. E., Pruitt, W. R., Conn, L. A., Perkins, B. A., Stephens, D. S., Baughman, W. S., Reingold, A. L., Rothrock, G. A., Pfaller, M. A., et al. (1999) · Clinical Infectious Diseases · doi:10.1086/313450 · Cited by 457
Self-citationEdwards, Jr., Bodey, G. P., Bowden, R. A., Buchner, T., de Pauw, B. E., Filler, S. G., Ghannoum, M. A., Glauser, M., Herbrecht, R., Kauffman, C. A., et al. (1997) · Clinical Infectious Diseases · doi:10.1086/514504 · Cited by 418
Self-citationPfaller, M. A., Jones, R. N., Messer, S. A., Edmond, M. B., & Wenzel, R. P. (1998) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/s0732-8893(97)00192-2 · Cited by 424
Self-citationEggimann, P., & Pittet, D. (2001) · Chest · doi:10.1378/chest.120.6.2059 · Cited by 395
Pfaller, M. A., Jones, R. N., Doern, G. V., Sader, H. S., Messer, S. A., Houston, A., Coffman, S., Hollis, R. J., & The SENTRY Participant Group (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.3.747-751.2000 · Cited by 378
Self-citationGroll, A. H., Piscitelli, S. C., & Walsh, T. J. (1998) · Advances in pharmacology · doi:10.1016/s1054-3589(08)60129-5 · Cited by 377
Has antifungal susceptibility testing come of age
Rex, J. H., & Pfaller, M. A. (2002) · Clinical Infectious Diseases · doi:10.1086/342384 · Cited by 361
“Although there is a great deal of experimental and pharmacodynamic support for the currently recommended fluconazole breakpoints [26, 27], the results of the 2 studies mentioned previously [24, 25] do not clearly indicate a useful interpretive breakpoint.”
BackgroundResultSelf-citationAmphotericin B and Other Polyenes—Discovery, Clinical Use, Mode of Action and Drug Resistance
Carolus, H., Pierson, S., Lagrou, K., & Van Dijck, P. (2020) · Journal of Fungi · doi:10.3390/jof6040321 · Cited by 349
Sanglard, D., Ischer, F., Calabrese, D., Majcherczyk, P. A., & Bille, J. (1999) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.43.11.2753 · Cited by 337
Pfaller, M. A., Jones, R. N., Messer, S. A., Edmond, M. B., & Wenzel, R. P. (1998) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/s0732-8893(97)00240-x · Cited by 331
Self-citationFitness Trade-offs Restrict the Evolution of Resistance to Amphotericin B
Vincent, B. M., Lancaster, A. K., Scherz-Shouval, R., Whitesell, L., & Lindquist, S. (2013) · PLoS Biology · doi:10.1371/journal.pbio.1001692 · Cited by 322
“Certainly, AmB therapy often fails, but not because the fungus acquires resistance to the drug [44,45].”
BackgroundSanguinetti, M., Posteraro, B., Fiori, B., Ranno, S., Torelli, R., & Fadda, G. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.2.668-679.2005 · Cited by 319
Pharmacology of Systemic Antifungal Agents
Ashley, E. S. D., Lewis, R., Lewis, J. S., Martin, C., & Andes, D. (2006) · Clinical Infectious Diseases · doi:10.1086/504492 · Cited by 313
Antifungal drug resistance to azoles and polyenes
Canuto, M. M., & Rodero, F. G. (2002) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(02)00371-7 · Cited by 310
Pfaller, M. A., Diekema, D. J., & Sheehan, D. J. (2006) · Clinical Microbiology Reviews · doi:10.1128/cmr.19.2.435-447.2006 · Cited by 295
Self-citationPfaller, M. A., Houston, A., & Coffmann, S. (1996) · Journal of Clinical Microbiology · doi:10.1128/jcm.34.1.58-61.1996 · Cited by 289
Self-citationPfaller, M. A., Jones, R. N., Doern, G. V., Sader, H. S., Hollis, R. J., Messer, S. A., & Group, F. T. S. P. (1998) · Journal of Clinical Microbiology · doi:10.1128/jcm.36.7.1886-1889.1998 · Cited by 281
Self-citationPhillips, P., Shafran, S., Garber, G., Rotstein, C., Smaill, F., Fong, I., Salit, I., Miller, M., Williams, K., Conly, J. M., et al. (1997) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/bf01726360 · Cited by 221
Nguyen, M. H., Clancy, C. J., Yu, V. L., Yu, Y. C., Morris, A. J., Snydman, D. R., Sutton, D. A., & Rinaldi, M. G. (1998) · The Journal of Infectious Diseases · doi:10.1086/514193 · Cited by 219
Pfaller, M. A., Messer, S. A., Hollis, R. J., Jones, R. N., Doern, G. V., Brandt, M. E., & Hajjeh, R. A. (1999) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/s0732-8893(98)00160-6 · Cited by 216
Self-citationWanger, A., Mills, K., Nelson, P. W., & Rex, J. H. (1995) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.39.11.2520 · Cited by 202
Self-citationDetection of amphotericin B-resistant Candida isolates in a broth-based system
Rex, J. H., Cooper, C. R., Merz, W. G., Galgiani, J. N., & Anaissie, E. J. (1995) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.39.4.906 · Cited by 198
Self-citationPfaller, M. A., Espinel-Ingroff, A., Canton, E., Castanheira, M., Cuenca-Estrella, M., Diekema, D. J., Fothergill, A., Fuller, J., Ghannoum, M., Jones, R. N., et al. (2012) · Journal of Clinical Microbiology · doi:10.1128/jcm.00248-12 · Cited by 174
Self-citationRapid Identification of Candida Species with Species-Specific DNA Probes
Elie, C. M., Lott, T. J., Reiss, E., & Morrison, C. J. (1998) · Journal of Clinical Microbiology · doi:10.1128/jcm.36.11.3260-3265.1998 · Cited by 159
SENDID, B., POIROT, J. L., TABOURET, M., BONNIN, A., CAILLOT, D., CAMUS, D., & POULAIN, D. (2002) · Journal of Medical Microbiology · doi:10.1099/0022-1317-51-5-433 · Cited by 156
Experimental Induction of Fluconazole Resistance in Candida tropicalis ATCC 750
Barchiesi, F., Calabrese, D., Sanglard, D., Falconi Di Francesco, L., Caselli, F., Giannini, D., Giacometti, A., Gavaudan, S., & Scalise, G. (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.6.1578-1584.2000 · Cited by 145
Candida glabrata Biofilms: How Far Have We Come?
Rodrigues, C., Rodrigues, M., Silva, S., & Henriques, M. (2017) · Journal of Fungi · doi:10.3390/jof3010011 · Cited by 129
Park, B. J., Arthington-Skaggs, B. A., Hajjeh, R. A., Iqbal, N., Ciblak, M. A., Lee-Yang, W., Hairston, M. D., Phelan, M., Plikaytis, B. D., Sofair, A. N., et al. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.50.4.1287-1292.2006 · Cited by 113
Candida lusitaniae: A Cause of Breakthrough Fungemia in Cancer Patients
Minari, A., Hachem, R., & Raad, I. (2001) · Clinical Infectious Diseases · doi:10.1086/318473 · Cited by 96
Revankar, S. G., Kirkpatrick, W. R., McAtee, R. K., Dib, O. P., Fothergill, A. W., Redding, S. W., Rinaldi, M. G., Hilsenbeck, S. G., & Patterson, T. F. (1998) · The American Journal of Medicine · doi:10.1016/s0002-9343(98)00137-5 · Cited by 67
Relationships between Respiration and Susceptibility to Azole Antifungals in Candida glabrata
Brun, S., Aubry, C., Lima, O., Filmon, R., Bergès, T., Chabasse, D., & Bouchara, J.-P. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.3.847-853.2003 · Cited by 64
Key issues concerning fungistatic versus fungicidal drugs
Graybill, J. R., Burgess, D. S., & Hardin, T. C. (1997) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/bf01575120 · Cited by 59
Advances in Candida detection platforms for clinical and point-of-care applications
Safavieh, M., Coarsey, C., Esiobu, N., Memic, A., Vyas, J. M., Shafiee, H., & Asghar, W. (2017) · Critical Reviews in Biotechnology · doi:10.3109/07388551.2016.1167667 · Cited by 57
Martins, M. D., Lozano‐Chiu, M., & Rex, J. H. (1997) · Clinical Infectious Diseases · doi:10.1086/515554 · Cited by 54
Self-citationT., B., W., F., H., B., N., B., K.-H., D., M., H., D., H., U., J., G., J.-N., M., K., et al. (2002) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-002-0730-4 · Cited by 53
Kovacicova, G., Krupova, Y., Lovaszova, M., Obertik, T., Krcmery, V., Roidova, A., Trupl, J., Liskova, A., Hanzen, J., Milosovic, P., et al. (2000) · Journal of Infection and Chemotherapy · doi:10.1007/s101560070006 · Cited by 39
Metadata
- Authors
- Rex, J. H., Pfaller, M. A., Barry, A. L., Nelson, P. W., & Webb, C. D.
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 1995-01
- Volume
- 39
- Issue
- 1
- Pages
- 40-44
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- OpenAlex
- W2074890764
- Cited by
- 301
- References
- 16
- FWCI
- 30.35
- Type
- journal article
- Language
- en
- Open access
- green
- Licence
- journals.asm.org/non-commercial-tdm-license (tdm)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.